In aggressive cancer stem cell-like/poorly differentiated oral tumor models, combined treatment with PD-1 antibody and super-enhanced NK cells not only significantly augmented NK cell-mediated cytotoxicity but also stimulated IFN-γ secretion, thereby improving therapeutic efficacy [71]. The gene discussed is PDCD1; the disease is cancer.